H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

Question: I have recently been diagnosed with sciatica and I am finding it difficult to do any exercise. My usual form of ...